Ovid Therapeutics Inc. is a company that develops therapies for rare neurological disorders. The company was founded in 2014 and is headquartered in New York, New York. Ovid Therapeutics Inc. focuses on developing treatments for Angelman syndrome, Fragile X syndrome, and other rare neurological disorders. The company's lead product candidate is OV101, which is in Phase III clinical trials for the treatment of Angelman syndrome and Fragile X syndrome. Ovid Therapeutics Inc. also has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize TAK-935, a product candidate for the treatment of rare pediatric epilepsies. The company's mission is to develop therapies that can improve the lives of patients with rare neurological disorders.